PARP inhibitor
Jump to navigation
Jump to search
Indications
- PARP inhibitors are FDA-approved to treat androgen-independent metastatic prostate cancer
- olaparib (Lynparza) is a poly ADP-ribose polymerase inhibitor FDA-approved to treat advanced ovarian cancer with germline BRCA mutations
- niraparib (Zejula) is a poly ADP-ribose polymerase inhibitor FDA-approved for maintenance treatment of recurrent epithelial cancers (ovarian cancer, fallopian tube cancer, primary peritoneal cancer)
Mechanism of action
- inhibitors of poly-ADP-ribose polymerase (PARP)
- current PARP inhibitors are also small inhibitory antineoplastic agents
More general terms
More specific terms
Additional terms
References
- ↑ Mittal K Genomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer - Prospective evidence supporting use of fresh biopsies rather than archival specimens for genomic profiling. MedPage Todau. ASCO Reading Room 12.02.2020 https://www.medpagetoday.com/reading-room/asco/non-prostate-genitourinary-cancer/89958
Gilson C, et al Genomic profiles of de novo high- and low-volume metastatic prostate cancer: Results from a 2-stage feasibility and prevalence study in the STAMPEDE trial/. JCO Precis Oncol 2020; 4: 882-897 Not indexed in PubMed https://ascopubs.org/doi/full/10.1200/PO.19.00388%C2%A0